

Rec'd PCT/PTO 13 DEC 2004

517594

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
WO 03/106451 A1

(51) International Patent Classification<sup>7</sup>: C07D 401/14,  
409/14, A61K 31/506, A61P 11/00, C07D 405/14

Konstanz (DE). ZAPF, James; 10871 Corte Playa Solana,  
SAN DIEGO, CA 92124 (US).

(21) International Application Number: PCT/EP03/06016

(72) Inventors; and

(22) International Filing Date: 7 June 2003 (07.06.2003)

(75) Inventors/Applicants (for US only): BAUDLER,  
Monika [DE/DE]; Döbelestr. 16, 78462 Konstanz (DE).  
BHAGWAT, Shripad, S. [US/US]; 5015 Ashley Falls  
Court, San Diego, CA 92130 (US). ERDMAN, Paul,  
E. [US/US]; 8510 Ivory Coast Drive, San Diego, CA  
92126 (US). GANTNER, Florian [AT/JP]; Unizon Do-  
gashiba 302, 1-5-40 Dogashiba, Osaka, Tennoji-Ku, Osaka  
543-0033 (JP). PALANKI, Moorthy S., S. [US/US];  
602 Crest Dr., Encinitas, CA 92024 (US). SCHUDT,  
Christian [DE/DE]; Schützenstrasse 20, 78462 Konstanz  
(DE). STADLWIESER, Josef [AT/DE]; Im Apfelgarten  
3, 78465 Konstanz (DE). ZAPF, James [US/US]; 10871  
Corte Playa Solana, San Diego, CA 92124 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/388,312 14 June 2002 (14.06.2002) US  
02013675.0 20 June 2002 (20.06.2002) EP

(71) Applicants (for all designated States except US): AL-  
TANA PHARMA AG [DE/DE]; Byk-Gulden-Str. 2,  
78467 Konstanz (DE). SIGNAL PHARMACEUTI-  
CALS, INC. [US/US]; c/o Celgene, 4550 Towne Centre  
Court, San Diego, CA 92121 (US).

(74) Agent: WOLF, Ulrich; c/o ALTANA Pharma AG, Byk-  
Gulden-Str. 2, 78462 Konstanz (DE).

(72) Inventors (for AE, AL, AM, AT, AU, AZ, BA, BE, BG, BR,  
BY, CA, CH, CN, CO, CU, CY, CZ, DE, DK, DZ, EC, EE,  
ES, FI, FR, GB, GE, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP,  
KG, KR, KZ, LT, LU, LV, MA, MC, MD, MK, MX, NL, NO,  
NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR,  
UA, US, VN, YU, ZA, ZW only): BAUDLER, Monika; Dö-  
belestr. 16, 78462 Konstanz (DE). BHAGWAT, Shripad,  
S.; 5015 Ashley Falls Court, San Diego, CA 92130 (US).  
ERDMAN, Paul, E.; 8229 Jade Coast #84, San Diego, CA  
92126 (US).

(81) Designated States (national): AE, AL, AU, BA, BR, CA,  
CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT,  
LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN,  
YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID,  
IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL,  
SG, TN, UA, VN, YU, ZA, ZW, Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID,  
IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL,  
SG, TN, UA, VN, YU, ZA, ZW, Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations

[Continued on next page]

(54) Title: SUBSTITUTED DIAMINOPYRIMIDINES

(57) Abstract: The invention relates to substituted diaminopyrimidine compounds, which are effective therapeutic compounds for  
treating diseases and disorders associated with those commonly treated by Protein Kinase C theta (PKCθ) inhibitors.

WO 03/106451 A1